Clinical and Scientific Research Reports for Theralase
Al and I recently meet up with Roger when he was passing through Vancouver and had a great chat. In the conversation Roger pointed us to a slide in his recent presentation that outlines a number of research reports that have been published in medical journals. Below is a list and links to these reports. I highly recommend reading over these reports, if you have not already done so, to better understand and build confidence in what Roger and his team is building.
We will also be having Roger join us on the weekend show for another update. Please email us your questions and we will do our best to address them in the interview.
Here are the reports with links…
1 Action of a Diode Laser in Orthopaedics and Traumatology
2 A Renaissance in Low-Level Laser Therapy
http://theralase.com/wp-content/uploads/2014/05/A-Renaissance-in-Low-Level-Laser-light-Therapy.pdf
3 A role of INOS Gene Expression in the Anti-Inflammatory and Tissue Protection Mechanisms of 905 nm Pulse
4 In-Vivo Effects of Low Level Laser Therapy on Inducible Nitric Oxide Synthase
5 Laser Therapy Applications for Osteoarthritis and Chronic Joint Pain – A Randomized Placebo Controlled Clinical Trial
6 Laser Acupuncture Therapy for the Treatment of Tobacco Addiction
http://theralase.com/wp-content/uploads/2014/05/Smoking-Cessation-Clinical-Study.pdf
7 A Double Blind Randomized Controlled Trial on the Effects of the TLC-2000 Therapeutic Laser System on Supraspinatus Rotator Cuff Injuries for Post Surgical Repair and Post Non-Surgical Repair
(Commencing in 3Q2016)
Ditto John’s questions
It seems the “goalposts” of the ITA keep moving. I remember in December being told by year end. In January, by February, and on and on.
When Health Canada communicates with Theralase, by what method are they communicating. Is it written correspondence? Why is there no clarity on timelines and why no updates to shareholders when the goalpost first moves. It seems we find out much, much later.
Thank you.
Please ask Roger how frequently HC is communicating with the company. I recall in December, the company indicating that by the end of the year we’d have ITA approval. That was over 6 months ago. Why are there no solid timelines for investors and why is the company not communicating with investors about the ITA?
If the probe’s sterilization is holding up the ITA, why not build 9 probes for the trial and tell the bureaucrats at HC that you will address the sterilization later and chose to make the probe a throw-away. Manufacturing advances may allow this to be cheaper over time and it is will be a recurring revenue stream for TLT.
EDIT Above: “may” chose to make the probe a throw away.
Would you be so kind to ask Roger Dumoulin-White whether he has re-submitted for an ITA approval to “Health Canada” concerning the “dosimetry fibre optic cage (DFOC)” which is going to be used in the Phase Ib clinical study? And if not: 1)What is the reason or what are the obstacles for the delay? 2) Especially regarding the burn rate factor and the pending need for future financing: When is one going to submit for this ITA?
Please ask Roger to provide an update on their cancer drug trials and best-guess timeline for advancing into possible full-scale production. Also, if possible, is the company experiencing any outside interest from other drug manufacturers at this point in time?